741 related articles for article (PubMed ID: 26780287)
1. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
[TBL] [Abstract][Full Text] [Related]
2. Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.
Lallukka S; Luukkonen PK; Zhou Y; Isokuortti E; Leivonen M; Juuti A; Hakkarainen A; Orho-Melander M; Lundbom N; Olkkonen VM; Lassila R; Yki-Järvinen H
Thromb Haemost; 2017 Jan; 117(2):286-294. PubMed ID: 27929200
[TBL] [Abstract][Full Text] [Related]
3. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3.
Lallukka S; Sevastianova K; Perttilä J; Hakkarainen A; Orho-Melander M; Lundbom N; Olkkonen VM; Yki-Järvinen H
Diabetologia; 2013 Apr; 56(4):886-92. PubMed ID: 23334462
[TBL] [Abstract][Full Text] [Related]
4. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
5. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
Hyysalo J; Gopalacharyulu P; Bian H; Hyötyläinen T; Leivonen M; Jaser N; Juuti A; Honka MJ; Nuutila P; Olkkonen VM; Oresic M; Yki-Järvinen H
Diabetes; 2014 Jan; 63(1):312-22. PubMed ID: 24009255
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
[TBL] [Abstract][Full Text] [Related]
7. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
[TBL] [Abstract][Full Text] [Related]
8. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
9. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.
Isokuortti E; Zhou Y; Peltonen M; Bugianesi E; Clement K; Bonnefont-Rousselot D; Lacorte JM; Gastaldelli A; Schuppan D; Schattenberg JM; Hakkarainen A; Lundbom N; Jousilahti P; Männistö S; Keinänen-Kiukaanniemi S; Saltevo J; Anstee QM; Yki-Järvinen H
Diabetologia; 2017 Oct; 60(10):1873-1882. PubMed ID: 28660493
[TBL] [Abstract][Full Text] [Related]
10. The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue.
Qadri S; Lallukka-Brück S; Luukkonen PK; Zhou Y; Gastaldelli A; Orho-Melander M; Sammalkorpi H; Juuti A; Penttilä AK; Perttilä J; Hakkarainen A; Lehtimäki TE; Orešič M; Hyötyläinen T; Hodson L; Olkkonen VM; Yki-Järvinen H
Liver Int; 2020 Sep; 40(9):2128-2138. PubMed ID: 32386450
[TBL] [Abstract][Full Text] [Related]
11. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation.
Franko A; Merkel D; Kovarova M; Hoene M; Jaghutriz BA; Heni M; Königsrainer A; Papan C; Lehr S; Häring HU; Peter A
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227635
[TBL] [Abstract][Full Text] [Related]
13. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
14. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
[TBL] [Abstract][Full Text] [Related]
15. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
[TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
[TBL] [Abstract][Full Text] [Related]
18. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
Matsuzaka T; Kuba M; Koyasu S; Yamamoto Y; Motomura K; Arulmozhiraja S; Ohno H; Sharma R; Shimura T; Okajima Y; Han SI; Aita Y; Mizunoe Y; Osaki Y; Iwasaki H; Yatoh S; Suzuki H; Sone H; Takeuchi Y; Yahagi N; Miyamoto T; Sekiya M; Nakagawa Y; Ema M; Takahashi S; Tokiwa H; Shimano H
Hepatology; 2020 May; 71(5):1609-1625. PubMed ID: 31529722
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]